Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

ceva sante animale (0000008501) avenue de la ballastiere, libourne, 33500 - live avian infectious bursal disease virus, strain winterfield 2512, g-61 - ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΓΙΑ ΕΝΕΩΡΗΜΑ - live avian infectious bursal disease virus, strain winterfield 2512, g-61 (8900000250) 0mg

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

intervet international bv (0000000669) wim de korvestraat 35, boxmeer, nl-5831 - virus newcastle strain la sota - powder for suspension for injection - 10-6eid50,1000 doses - virus newcastle strain la sota (8000000303) 0eid50

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

medivet suppliers co ltd (0000003012) 17 stasinos ave, 1508 lefkosia, p o box 21402 - virus parvovirus porcine, inactivated - suspension for injection - 9 log2 hui / 2 ml - virus parvovirus porcine, inactivated (8000030446) 0mg

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - Έρπητα Ζωστήρα - Εμβόλια - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. Η χρήση shingrix θα πρέπει να γίνεται σύμφωνα με τις επίσημες συστάσεις.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - Γρίπη, Ανθρώπινα - Εμβόλια - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - Εμβόλια - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - Δάγκειος πυρετός - Εμβόλια - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - Εμβόλια - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - ανθρώπινο ροταϊό, ζωντανό εξασθενημένο - immunization; rotavirus infections - Εμβόλια - Το rotarix ενδείκνυται για την ενεργό ανοσοποίηση βρεφών ηλικίας 6 έως 24 εβδομάδων για την πρόληψη γαστρεντερίτιδας λόγω μόλυνσης από ροταϊό. Η χρήση του rotarix θα πρέπει να βασίζεται σε επίσημη σύσταση.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

sanofi pasteur europe, france (0000011723) 14 espace henry vallee, lyon, 69007 - purified diphteria toxoid; purified tetanus toxoid; inactivated poliovirus vacc type i; inactivated poliovirus vacc type ii; inactivated poliovirus vacc type iii; aluminium hydroxide - ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - 0,5ml - ineof00246 purified diphteria toxoid 2.000000 iu; ineof00247 purified tetanus toxoid 20.000000 iu; ineof00249 inactivated poliovirus vacc type i 40.000000; ineof00250 inactivated poliovirus vacc type ii 8.000000; ineof00251 inactivated poliovirus vacc type iii 32.000000; 0021645512 aluminium hydroxide 0.350000 mg - diphtheria-poliomyelitis-tetanus